A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex®

Main measures

• The primary objective of the study is to evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing MS. The number and percentage of subjects who develop NAbs to IFN-beta is the primary endpoint in the evaluation of immunogenicity.

  Immune response

• Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting

  Phase 3 · Not yet recruiting

  Still running

• Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

  Recruiting

  Still running

• Discontinuation of first-line disease modifying treatment (DMT) in lon

  Phase 4 · Stopped early

  Stopped

• A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY

  Running, not recruiting

  Still running

• Study to Investigate Pregnancy Outcomes in Female Participants Exposed

  Completed

  Paper found, not read

• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017

  Phase 3 · Running, not recruiting

  Still running

1. Oct 2026In scope changed from true to false

1. Started

   Oct 2008